ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2024 · 112 positions · Total reported value $4.61B · Top-10 concentration 46.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2024 13F filing, ORBIMED ADVISORS LLC disclosed 112 equity positions with a combined reported value of $4.61B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 46.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were EWTX ($401.08M), SVA ($334.00M), BSX ($282.28M). By sector, the heaviest allocations are Health Care 82.6%, Industrials 1.0%. Versus the prior quarter, allocation shifted toward Other (+1.5pp) and away from Health Care (-1.4pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 70% of names.

The largest new positions opened in Q4 2024 were UPB ($93.60M), EW ($84.79M), XBI ($33.50M).

Of the 23 positions fully exited versus the prior quarter, the largest were AMGN ($81.29M), ELV ($55.22M), REGN ($47.52M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • UPB UPSTREAM BIO INC COM · $93.60M
  • EW EDWARDS LIFESCIENCES CORP · $84.79M
  • XBI SPDR SERIES TRUST · $33.50M
  • RAPT RAPT THERAPEUTICS INC · $20.75M
  • FBRX FORTE BIOSCIENCES INC · $13.63M
  • ITCI INTRA-CELLULAR THERAPIES INC · $13.61M
  • CRDF CARDIFF ONCOLOGY INC · $6.68M
  • PFE PFIZER INC · $6.63M

Fully Exited (vs previous quarter)

  • AMGN AMGEN INC · prev qtr: $81.29M
  • ELV ELEVANCE HEALTH INC FORMERLY · prev qtr: $55.22M
  • REGN REGENERON PHARMACEUTICALS · prev qtr: $47.52M
  • PCVX VAXCYTE INC COM · prev qtr: $44.22M
  • SNDX SYNDAX PHARMACEUTICALS INC COM · prev qtr: $37.06M · history
  • APLS APELLIS PHARMACEUTICALS INC · prev qtr: $36.64M
  • ICLR ICON PUB LTD CO SHS · prev qtr: $35.60M
  • PHAT PHATHOM PHARMACEUTICALS INC · prev qtr: $26.20M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 82.6%
Other 16.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 15.02M $401.08M 8.70%
8.70%
Hold
2 2.72M $334.00M 7.25%
7.25%
Hold
3 3.16M $282.28M 6.12%
6.12%
Reduce
4 337.60K $260.63M 5.66%
5.66%
Hold
5 401.70K $209.67M 4.55%
4.55%
Reduce
6 7.96M $179.09M 3.89%
3.89%
Hold
7 938.12K $128.05M 2.78%
2.78%
Add
8 344.40K $124.00M 2.69%
2.69%
Hold
9 963.40K $117.14M 2.54%
2.54%
Add
10 189.70K $116.67M 2.53%
2.53%
Reduce
11 1.79M $113.21M 2.46%
2.46%
Hold
12 2.82M $98.49M 2.14%
2.14%
Add
13 415.60K $97.79M 2.12%
2.12%
Add
14 5.69M $93.60M 2.03%
2.03%
New
15 8.29M $87.44M 1.90%
1.90%
Hold
16 1.15M $84.79M 1.84%
1.84%
New
17 829.90K $82.56M 1.79%
1.79%
Reduce
18 3.03M $80.65M 1.75%
1.75%
Hold
19 509.10K $77.85M 1.69%
1.69%
Reduce
20 575.00K $76.20M 1.65%
1.65%
Hold
21 1.58M $74.51M 1.62%
1.62%
Add
22 3.81M $70.26M 1.52%
1.52%
Hold
23 130.90K $66.22M 1.44%
1.44%
Reduce
24 413.00K $65.38M 1.42%
1.42%
Reduce
25 151.00K $60.81M 1.32%
1.32%
Hold
26 5.78M $59.47M 1.29%
1.29%
Hold
27 999.00K $51.08M 1.11%
1.11%
Reduce
28 1.26M $45.34M 0.98%
0.98%
Reduce
29 84.40K $43.91M 0.95%
0.95%
Hold
30 7.56M $41.90M 0.91%
0.91%
Hold
31 1.43M $41.04M 0.89%
0.89%
Add
32 758.57K $40.61M 0.88%
0.88%
Reduce
33 679.82K $38.20M 0.83%
0.83%
Hold
34 3.41M $38.12M 0.83%
0.83%
Hold
35 947.88K $37.16M 0.81%
0.81%
Add
36 6.94M $37.15M 0.81%
0.81%
Hold
37 372.00K $33.50M 0.73%
0.73%
New
38 22.36M $32.43M 0.70%
0.70%
Hold
39 73.11M $32.39M 0.70%
0.70%
Hold
40 1.11M $32.36M 0.70%
0.70%
Add
41 742.57K $31.40M 0.68%
0.68%
Add
42 1.23M $28.91M 0.63%
0.63%
Add
43 1.94M $23.66M 0.51%
0.51%
Add
44 3.22M $23.62M 0.51%
0.51%
Reduce
45 400.00K $22.39M 0.49%
0.49%
Reduce
46 3.09M $21.95M 0.48%
0.48%
Add
47 2.29M $21.53M 0.47%
0.47%
Add
48 6.06M $21.45M 0.47%
0.47%
Hold
49 13.14M $20.75M 0.45%
0.45%
New
50 1.47M $20.43M 0.44%
0.44%
Add

FAQ

What did ORBIMED ADVISORS LLC buy in 2024-Q4?

In its 2024-Q4 13F filing, ORBIMED ADVISORS LLC reported 112 equity positions worth $4.61B in aggregate; its largest disclosed positions were EWTX ($401.08M), SVA ($334.00M), BSX ($282.28M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.61B of long equity holdings across 112 positions as of 2024-Q4. Top-10 holdings account for 46.7% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →